Granite Point Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Granite Point Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150,000	Closed	-$14.4M	–	147
2021 Q3	$14.4M	Sell	150,000 -100,000	-40%	-$9.45M	1.1%	8
2021 Q2	$24.3M	Buy	+250,000	New	+$24M	0.9%	7

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Granite Point Capital Management's NBIX Position: Q1 2015 in Review

Granite Point Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2015, closing a stake of 40,000 shares — an estimated $894K sold.

Granite Point Capital Management first reported a position in NBIX in Q4 2013 and held it in 5 quarters. The position peaked at $1.04M in Q1 2014. 175 funds tracked by Wall St. Rank hold NBIX as of Q1 2015.

Granite Point Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2015 after selling out during the quarter.
Granite Point Capital Management sold 40,000 Neurocrine Biosciences shares in Q1 2015, an estimated $894K.
Granite Point Capital Management first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 5 quarters.
Granite Point Capital Management's Neurocrine Biosciences position peaked at $1.04M in Q1 2014.
175 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2015.

Based on Granite Point Capital Management's 13F filing for Q1 2015, filed 14 May 2015.